Decision Resources, Inc., one of the world's leading research and advisory firms focusing on pharmaceutical and health care issues, finds that Sanofi-Aventis's Acomplia, a novel cannabinoid CB1 receptor antagonist, will have a huge impact on the obesity drug market. According to a new Pharmacor study entitled Obesity, the market will reach $2.3 billion in 2013 primarily driven by the strength of Acomplia's sales. Set to launch in 2006, Acomplia is poised to become the first antiobesity agent to achieve blockbuster status.

The study also finds that lack of reimbursement for weigh-loss therapies results in out-of-pocket expenses of approximately $3 per day for two leading antiobesity agents: orlistat (Roche's Xenical) and sibutramine (Abbott's Meridia and AstraZeneca's Reductil).

"The high cost of these therapies is the top reason for noncompliance and discontinuation of drug therapy," said Donny Wong, Ph.D., analyst at Decision Resources. "According to physicians that we interviewed, many patients cannot afford to refill their prescriptions. Therefore, a significant commercial opportunity exists for agents that can offer safety and efficacy profiles similar to those of orlistat and sibutramine, but at a reduced cost."

About Obesity

The prevalence of obesity has reached epidemic proportions in the United States and Europe. The U.S. Centers for Disease Control and Prevention predicts that obesity-related deaths will soon overtake smoking-related illnesses as the leading cause of mortality in the United States.

About Pharmacor from Decision Resources

Pharmacor is a unique family of studies that assesses a host of market- impacting factors and analyzes the commercial outlook for drugs in research and development.

About Decision Resources

Decision Resources, Inc., ( is a world leader in market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

  For more information, contact:    Elizabeth Marshall    Decision Resources, Inc.    781-296-2563 

SOURCE: Decision Resources, Inc.

CONTACT: Elizabeth Marshall of Decision Resources, Inc., +1-781-296-

Generic Erosion to Significantly Stunt the Growth of the Bipolar Disorder Drug Market in the United States

View Now